Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy ... loss of 22% after 36 weeks.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Neither medication is available over the counter from a pharmacy, as you will need to be assessed for suitability before ... hospitalised after using weight loss drugs last year. The MHRA said ...

Now, a new study finds that Ozempic, along with similar drugs such as Wegovy, has had a broad ... users spent 6% less on groceries than before they started the drug, with higher-income households ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Wegovy: sales of weight loss injection more than double - The company said more than 45 million people were now ‘benefitting ...